Dementia is a condition that results in progressive memory or thinking problems. It’s now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer’s ...

Eisai Co., Ltd. and Biogen Inc. announced that the European Commission has granted marketing authorization for lecanemab, marketed as Leqembi®, making it the first therapy in the EU to target an ...

Please provide your email address to receive an email when new articles are posted on . Patients initially received placebo then used lecanemab from 18 through 48 months. Treatment outcomes were ...